The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
Beleaguered Canadian drugmaker Valeant Pharmaceuticals International filed its long-delayed annual report on Friday, in which it identified misstatements that would reduce some of its previously reported revenue.
Valeant said it was in compliance with its credit agreement and senior note indentures and that no additional restatements were required beyond those previously disclosed.
The filing of the report will help the company stave off a possible default on its $30 billion debt.
The company had said it would file the report by April 29, although it had an extension agreement with its creditors to delay the filing until June 11.
The Laval, Quebec-based company's U.S-listed stock fell about 2 percent in premarket trade.
The company also said it had received a document subpoena from the New Jersey state bureau of securities on April 20.
The company said the restatement reduced previously reported fiscal 2014 revenue by about $58 million, net income attributable to its shareholders by about $33 million, and earnings per share by 9 cents.
The restatement for the first quarter of 2015 lowered revenue by about $21 million, but increased net income attributable to Valeant by about $24 million and earnings per share by 7 cents.
Valeant has been facing scrutiny from the U.S. Congress, prosecutors and regulators over its drug pricing, business practices and accounting practices — issues that have caused its share price to plummet almost 90 percent since August.